IP Library Granted Patent US 9,864,102
Granted Patent B2
US 9,864,102 · App. 14/967,780 · Granted Jan 9, 2018

Hydrophobic acrylate-acrylamide copolymers for ophthalmic devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,864,102
App. No.
14/967,780
Granted
Jan 9, 2018
Kind
B2
Abstract

Acrylate-acrylamide copolymers are disclosed. They are rigid and glassy in dry state at room temperature (from about 23° C. to about 28° C.), but are soft and very deformable and have a high refractive index, a high glistening resistance and a low aging-related surface light scattering in fully hydrated state. They are particularly suitable for making wet-packed intraocular lenses (IOLs) which can be delivered through sub 2.0 mm incisions.

Claims (39)

1. A polymeric ophthalmic device material, which is polymerization product of a polymerizable composition comprising

(a) from about 20% to about 35% by weight of N,N dimethylacrylamide relative to the total amount of all polymerizable components,

(b) from about 60% to about 70% by weight of one or more aryl acrylic monomers of formula (I) relative to the total amount of all polymerizable components

 wherein A 1 is H or CH 3 ; B 1 is (CH 2 ) m1 or [O(CH 2 ) 2 ] z1 in which m1 is 2-6 and z1 is 1-10; Y 1 is a direct bond, O, S, or NR′ in which R′ is H, CH 3 , C n′ H 2n′+1 in which n′=1-10, iso-OC 3 H 7 , C 6 H 5 , or CH 2 C 6 H 5 ; W1 is 0-6, provided that m1+w1≦8; and D 1 is H, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 6 H 5 , or CH 2 C 6 H 5 ,

(c) a polymerizable crosslinking agent,

wherein the listed components and any additional polymerizable components add up to 100% by weight,

wherein the sum of the amounts of components (a) and (b) is at least 90% by weight,

wherein the ophthalmic device material in a dried state has a glass transition temperature of from about 28° C. to about 40° C.,

wherein the ophthalmic device material in a fully-hydrated state has: a glass transition temperature of less than 20° C., a refractive index of greater than 1.50 measured at 589 nm and at room temperature (23±3° C.), an equilibrium water content of from about 1.5% to about 3.9% by weight at a temperature of from 16° C. to 45° C., a glistening resistance characterized by having no bright field microvacuole and about 10 or less microvacuoles per viewing screen, a Young's modulus of from about 1.0 MPa to about 60.0 MPa, an elongation at break of greater than 90%, and a 25% secant modulus of less than 6.0 MPa.

2. The ophthalmic device material of claim 1 , wherein the device material in the fully hydrated state remains substantially clear or clear, as characterized by having

T

23

-

T

35

T

23

20

%

,

in which T 23 and T 35 are average transmittances between 400 nm to 700 nm of the material at 23° C. and 35° C. respectively when being heated from 23° C. to 35° C.

3. The ophthalmic device material of claim 2 , wherein the device material in the fully hydrated state has a surface light scattering of about 30 CCT or less after 10-years accelerated aging.

4. The ophthalmic device material of claim 2 , wherein in formula (I), B 1 is (CH 2 ) m1 , m1 is 2-5, Y 1 is nothing or O, w1 is 0 or 1, and D 1 is H.

5. The ophthalmic device material of claim 4 , wherein said one or more aryl acrylic monomers are: 2-ethylphenoxy acrylate; 2-ethylphenoxy methacrylate; phenyl acrylate; phenyl methacrylate; benzyl acrylate; benzyl methacrylate; 2-phenylethyl acrylate; 2-phenylethyl methacrylate; 3-phenylpropyl acrylate; 3-phenylpropyl methacrylate; 4-phenylbutyl acrylate; 4-phenylbutyl methacrylate; 4-methylphenyl acrylate; 4-methylphenyl methacrylate; 4-methylbenzyl acrylate; 4-methylbenzyl methacrylate; 2-2-methylphenylethyl acrylate; 2,2-methylphenylethyl methacrylate; 2,3-methylphenylethyl acrylate; 2,3-methylphenylethyl methacrylate; 2,4-methylphenylethyl acrylate; 2,4-methylphenylethyl methacrylate; 2-(4-propylphenyl)ethyl acrylate; 2-(4-propylphenyl)ethyl methacrylate; 2-(4-(1-methylethyl)phenyl)ethyl acrylate; 2-(4-(1-methylethyl)phenyl)ethyl methacrylate; 2-(4-methoxyphenyl)ethyl acrylate; 2-(4-methoxyphenyl)ethyl methacrylate; 2-(4-cyclohexylphenyl)ethyl acrylate; 2-(4-cyclohexylphenyl)ethyl methacrylate; 2-(2-chlorophenyl)ethyl acrylate; 2-(2-chlorophenyl)ethyl methacrylate; 2-(3-chlorophenyl)ethyl acrylate; 2-(3-chlorophenyl)ethyl methacrylate; 2-(4-chlorophenyl)ethyl acrylate; 2-(4-chlorophenyl)ethyl methacrylate; 2-(4-bromophenyl)ethyl acrylate; 2-(4-bromophenyl)ethyl methacrylate; 2-(3-phenylphenyl)ethyl acrylate; 2-(3-phenylphenyl)ethyl methacrylate; 2-(4-phenylphenyl)ethyl acrylate; 2-(4-phenylphenyl)ethyl methacrylate; 2-(4-benzylphenyl)ethyl acrylate; 2-(4-benzylphenyl)ethyl methacrylate; 2-(phenylthio)ethyl acrylate; 2-(phenylthio)ethyl methacrylate; 2-benzyloxyethyl acrylate; 3-benzyloxypropyl acrylate; 2-benzyloxyethyl methacrylate; 3-benzyloxypropyl methacrylate; 2-[2-(benzyloxy)ethoxy]ethyl acrylate; 2-[2-(benzyloxy)ethoxy]ethyl methacrylate; or combinations thereof.

6. The ophthalmic device material of claim 5 , wherein said one or more aryl acrylic monomers are: 2-phenylethyl acrylate; 3-phenylpropyl acrylate; 4-phenylbutyl acrylate; 5-phenylpentyl acrylate; 2-benzyloxyethyl acrylate; 3-benzyloxypropyl acrylate; 2-[2-(benzyloxy)ethoxy]ethyl acrylate; or combinations thereof.

7. The ophthalmic device material of claim 6 , wherein the polymerizable composition comprises from about 1.0% to about 6.0% by weight of the polymerizable crosslinking agent.

8. The ophthalmic device material of claim 7 , wherein the polymerizable crosslinking agent is selected from the group consisting of ethylene glycol dimethacrylate; diethylene glycol dimethacrylate; triethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, allyl methacrylate; 1,3-propanediol dimethacrylate; 2,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate; ethylene glycol diacrylate; diethylene glycol diacrylate; triethylene glycol diacrylate, tetraethylene glycol diacrylate, allyl acrylate; 1,3-propanediol diacrylate; 2,3-propanediol diacrylate; 1,6-hexanediol diacrylate; 1,4-butanediol diacrylate; N,N′-hexamethylene bisacrylamide; N,N′-hexamethylene bismethacrylamide; N,N′-dihydroxyethylene bisacrylamide; N,N′-dihydroxyethylene bismethacrylamide; N,N′-methylene bisacrylamide; N,N′-methylene bismethacrylamide; CH 2 ═C(CH 3 )C(═O)O—(CH 2 CH 2 O) p —C(═O)C(CH 3 )═CH 2 where p=1-50; CH 2 ═CHC(═O)O—(CH 2 CH 2 O) p —C(═O)CH═CH 2 where p=1-50; CH 2 ═C(CH 3 )C(═O)O(CH 2 ) t O—C(═O)C(CH 3 )═CH 2 where t=3-20; CH 2 ═CHC(═O)O(CH 2 ) t O—C(═O)CH═CH 2 where t=3-20, and combinations thereof.

9. The ophthalmic device material of claim 5 , wherein the polymerizable composition comprises from about 1.0% to about 6.0% by weight of the polymerizable crosslinking agent.

10. The ophthalmic device material of claim 9 , wherein the polymerizable crosslinking agent is selected from the group consisting of ethylene glycol dimethacrylate; diethylene glycol dimethacrylate; triethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, allyl methacrylate; 1,3-propanediol dimethacrylate; 2,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate; ethylene glycol diacrylate; diethylene glycol diacrylate; triethylene glycol diacrylate, tetraethylene glycol diacrylate, allyl acrylate; 1,3-propanediol diacrylate; 2,3-propanediol diacrylate; 1,6-hexanediol diacrylate; 1,4-butanediol diacrylate; N,N′-hexamethylene bisacrylamide; N,N′-hexamethylene bismethacrylamide; N,N′-dihydroxyethylene bisacrylamide; N,N′-dihydroxyethylene bismethacrylamide; N,N′-methylene bisacrylamide; N,N′-methylene bismethacrylamide; CH 2 ═C(CH 3 )C(═O)O—(CH 2 CH 2 O) p —C(═O)C(CH 3 )═CH 2 where p=1-50; CH 2 ═CHC(═O)O—(CH 2 CH 2 O) p —C(═O)CH═CH 2 where p=1-50; CH 2 ═C(CH 3 )C(═O)O(CH 2 ) t O—C(═O)C(CH 3 )═CH 2 where t=3-20; CH 2 ═CHC(═O)O(CH 2 ) t O—C(═O)CH═CH 2 where t=3-20, and combinations thereof.

11. The ophthalmic device material of claim 2 , wherein the polymerizable composition further comprises at least one component selected from the group consisting of:

(i) hydroxyethyl methacrylate;

(ii) from about 1% to about 5% by weight of a poly(ethylene glycol)-containing polymerizable component of formula (II)

 wherein: A 2 is H or CH 3 ; Q 2 and Q 2 ′ independent of each other are a direct bond, O, NH, or C(═O)NHCH 2 CH 2 O; X 2 and X 2 ′ independent of each other are a direct bond, O, NH, OC(═O)NH, or NHC(═O)NH; R 2 and R 2 ′ independent of each other are a direct bond, or (CH 2 ) p ; p=1-3; G 2 is H, C 1 -C 4 alkyl, (CH 2 ) m2 NH 2 , (CH 2 ) m2 CO 2 H, or R 2 ′—X 2 ′-Q 2 ′-C(═O)CA 2 =CH 2 ; m2=2-6; and n2=45-225 when G=H, C 1 -C 4 alkyl, (CH 2 ) m2 NH 2 , or (CH 2 ) m2 CO 2 H; otherwise, n2=51-225; and

(iii) a combination thereof.

12. The ophthalmic device material of claim 11 , wherein the poly(ethylene glycol)-containing polymerizable component of formula (II) has a number average molecular weight of 2,000-10,000 Daltons.

13. The ophthalmic device material of claim 1 , wherein the polymerizable composition comprises a polymerizable UV-absorbing agent.

14. An intraocular lens comprising an ophthalmic device material of claim 1 .

Assignments (3)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2016
From: LAREDO, WALTER; AKINAY, ALI E.; JIANG, XUWEI; JINKERSON, DAVID; NGUYEN, VINCENT; SCHLUETER, DOUGLAS
To: ALCON RESEARCH, LTD.
Reel/Frame 038377/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2016
From: ALCON RESEARCH, LTD.
To: NOVARTIS AG
Reel/Frame 038377/0882 →